References
- Uzan J, Carbonnel M, Piconne O, et al. Pre-eclampsia: pathophysiology, diagnosis, and management. Vasc Health Risk Manag. 2011; 7: 467–474.
- Eiland E, Nzerue C, Faulkner M. Preeclampsia. J Pregnancy. Jul 11 2012; 586578.
- ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2019 Jan;133(1):1.
- Prakash J, Ganiger VC. Acute Kidney Injury in Pregnancy-specific Disorders. Indian J Nephrol. 2017; 27(4):258-70.
- Stanhewicz AE. Residual vascular dysfunction in women with a history of preeclampsia. Am J Physiol Regul Integr Comp Physiol. 2018 Dec 1;315(6):R1062-R1071.
- Mol BWJ, Roberts CT, Thangaratinam S, et al. Pre-eclampsia. Lancet. 2016;387:999–1011.
- Mohseni Z, Derksen E, Oben J, et al. Cardiac dysfunction after preeclampsia; an overview of pro- and anti-fibrotic circulating effector molecules. Pregnancy Hypertens. 2021 Mar;23:140-154.
- Smith GN, Walker MC, Liu A, et al. Pre-Eclampsia New Emerging Team (PE-NET). A history of preeclampsia identifies women who have underlying cardiovascular risk factors. Am J Obstet Gynecol. 2009 Jan;200(1):58.e1-8.
- Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974.
- Benschop L, Duvekot JJ, Versmissen J, et al, Roeters van Lennep JE. Blood Pressure Profile 1 Year After Severe Preeclampsia. Hypertension. 2018 Mar;71(3):491-498.
- Kuenzli A, Bucher HC, Anand I. et al. Metaanalysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PLoS One 2010, 5: e9946.
- Heusch G, Libby P, Gersh B. Cardiovascular remodeling in coronary artery disease and heart failure. Lancet. 2014, 383: 1933-1943.
- Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007; 292: 82–97.
- Hladunewich MA, Kingdom J, Odutayo A, K. Postpartum assessment of the renin angiotensin system in women with previous severe, early-onset preeclampsia, J. Clin. Endocrinol. Metab. 2011;96(11): 3517–3524.
- Seely EW, Rich-Edwards J, Lui J, et al. Risk of future cardiovascular disease in women with prior preeclampsia: a focus group study. BMC Pregnancy Childbirth. 2013 Dec 21;13:240.
- Zhang L, Tian J, Zhou Y, et al. Angiotensin-(1-7) attenuates damage to podocytes induced by preeclamptic serum through MAPK pathways. Int J Mol Med. 2014 Oct;34(4):1057-64.
- Spaan J, Brown M. Renin-angiotensin system in pre-eclampsia: everything old is new again. Obstet Med. 2012 Dec;5(4):147-153
- De Lima ASD, Holanda IP, Nascimento PRP, et al. Plasma angiotensin II levels in women with severe preeclampsia under magnesium sulphate regimen. Pregnancy Hypertens. 2021; 23: 56-58.
- Leaños-Miranda A, Campos-Galicia I, Ramírez-Valenzuela KL, et al. Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia. Hypertension. 2013 May;61(5):1118-25.
- Van der Graaf AM, Toering TJ, Faas MM, Titia Lely A. From preeclampsia to renal disease: a role of angiogenic factors and the renin-angiotensin aldosterone system? Nephrol. Dial. Transplant. 2012; 27 (suppl 3) iii51–iii57.
- Stanhewicz AE, Jandu S, Santhanam L, Alexander LM. Increased angiotensin II sensitivity contributes to microvascular dysfunction in women who have had preeclampsia. Hypertension. 2017; 70(2):382-389.
- Kim SY, Ryu HM, Yang JH, et al. Maternal serum levels of VCAM-1, ICAM-1 and E-selectin in preeclampsia. J Korean Med Sci. 2004 Oct;19(5):688-92.
- Verhaar MC, Rabelink TJ. The endothelium: a gynecological and obstetric point of view. Eur J Obst Gyn Reprod Biol 2001; 94: 180-5.
- Roberts JM, Taylor RN, Musci TJ, et al.. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989; 161; 1200-4.
- Krauss T, et al. Circulating endothelial cell adhesion molecules as diagnostic markers for the early identification of pregnant women at risk for development of preeclampsia. Am J Obst Gynecol 1997; 177: 443-9.
- Sibai BM. Risk factors, pregnancy complications, and prevention of hypertensive disorders in women with pregravid diabetes mellitus. J Matern-Fetal Med 2000; 9: 62-5.
- Sugi T, Makino T. Autoantibodies to contact proteins in patients with recurrent pregnancy losses. J Reprod Immunol 2002; 53: 269-77.
- Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999; 353: 1348-53.
- Levin ER. Endothelins. N Engl J Med. 1995; 333: 356-363.
- Hinson JP, Kapas S, et al. Adrenomedullin, a multifunctional regulatory peptide. Еndocrinol Rev. 2000; 21: 138-167.
- Landry DW, Oliver JA. Insights into shock. Sci Am. 2004; 290: 36–41.
- Christ-Crain M, Morgenthaler NG, et al. Mid-regional proadrenomedullin as a prognostic marker in sepsis: An observational study. Critical Care. 2005; 9(6): R816–R824.
- Tuzcu ZB, Asicioglu E, Sunbul M, et al. Circulating endothelial cell number and markers of endothelial dysfunction in previously preeclamptic women. Am J Obstet Gynecol. 2015 Oct;213(4):533.e1-7.
- Vickers M, Ford I, Morrison R, et al. Markers of endothelial activation and atherothrombosis in women with history of preeclampsia or gestational hypertension. Thromb Haemost. 2003 Dec;90(6):1192-7.
- European Society of Cardiology (ESC) Guideline for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39(34): 3165–3241.
- Behrens I, Basit S, Melbye M, et al. Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study. BMJ. 2017;358:j3078.
- Breetveld NM, Ghossein-Doha C, Van Kuijk S, et al. Cardiovascular disease risk is only elevated in hypertensive, formerly preeclamptic women. BJOG. 2015;122:1092–1100.
- Bushnell C, Chireau M. Preeclampsia and stroke: risks during and after pregnancy. Stroke Res Treat. 2011;2011:858134.
- Wenger NK. Recognizing pregnancy-associated cardiovascular risk factors. Am J Cardiol. 2014;113(2):406-409.
- Heidema WM, Scholten RR, Lotgering FK, et al. History of preeclampsia is more predictive of cardiometabolic and cardiovascular risk factors than obesity. Eur J Obstet Gynecol Reprod Biol. 2015;194:189-193.
- Bokslag A, Teunissen PW, Franssen C, et al. Effect of early-onset preeclampsia on cardiovascular risk in the fifth decade of life. Am J Obstet Gynecol. 2017;216:523.e1–523.e7.
- Mendoza-Torres E, Oyarzún A, Mondaca-Ruff D, et al. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Ther Adv Cardiovasc Dis. 2015 Aug;9(4):217-37.
- Wallukat G, Homuth V, Fischer T. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999; 103(7): 945–952.
- Siddiqui AH, Irani RA, Blackwell SC. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension 2010; 55(2): 386–393.
- Irani RA, Xia Y. Renin angiotensin signaling in normal pregnancy and preeclampsia. Semin Nephrol. 2011; 31:47–58.
- Irani RA, Xia Y. The functional role of the renin–angiotensin system in pregnancy and preeclampsia. Placenta 2008;29(9): 763–771.
- Shah DM. Role of the renin-angiotensin system in the pathogenesis of preeclampsia, Am J Physiol-Renal Physiol 2005; 288 (4): F614–F625.
- Rodriguez M, Moreno J, Hasbun J. RAS in pregnancy and preeclampsia and eclampsia, Int J Hypertension. 2012:1–6.
- Van der Graaf AM, Toering TJ, Faas MM, Titia Lely A. From preeclampsia to renal disease: a role of angiogenic factors and the renin-angiotensin aldosterone system? Nephrol Dial Transplant. 2012; 27 (suppl 3): iii51–iii57.
- Hladunewich MA, Kingdom J, Odutayo A, et al. Postpartum assessment of the renin angiotensin system in women with previous severe, early-onset preeclampsia, J Clin Endocrinol Metab. 2011; 96(11): 3517–3524.
- Saxena AR, Seely EW, Goldfine AB. Cardiovascular risk factors and menstrual cycle phase in pre-menopausal women. J Endocrinol Invest. 2012 Sep;35(8):715-9.
- Saxena AR, Karumanchi SA, Brown NJ, et al. Increased sensitivity to angiotensin II is present postpartum in women with a history of hypertensive pregnancy. Hypertension. 2010; 55:1239–1245.
- Zhang L, Zhou Y, Wu Q, et al. Effective prediction of preeclampsia by measuring serum angiotensin II, urinary angiotensinogen and urinary transforming growth factor β1. Exp Ther Med. 2017 Jul;14(1):391-397.
- Chase V, McBride C, Badger G, et al. Association of pre-pregnancy and longitudinal change in angiotensin-II with preterm preeclampsia. 2017, Poster session V| 216(1), Suppl., S530.
- Merrill DC, Karoly M, Chen K, et al. Angiotensin-(1-7) in normal and preeclamptic pregnancy. Endocrine. 2002 Aug;18(3):239-45.
- Brosnihan KB, Merrill DC, Yamaleyeva LM, et al. Longitudinal study of angiotensin peptides in normal and pre-eclamptic pregnancy. Endocrine. 2020 Aug;69(2):410-419.
- Leanos-Miranda A, Inova Campos-Galicia, Mendez-Aguilar F. Lower circulating angiotensin II levels are related to the severity of preeclampsia and its risk as disclosed by a specific bioassay. Medicine (Baltimore). 2018; 97(39): e12498.
- Baev O, Khlestova G, Romanov A. Changes of angiotensin II and angiotensin (1-7) levels in early and late-onset preeclampsia. Abstracts of European Journal of Obstetrics and Gynecology and Reproductive Biology. March 01, 2019 Session 10 – Obstetrics: Hypertension reference: a2286OB, Vol. 234, e26.
- Khlestova GV, Romanov AY, Nizyaeva NV, et al. Dynamics of Renin, Angiotensin II, and Angiotensin (1-7) during Pregnancy and Predisposition to Hypertension-Associated Complications. Bull Exp Biol Med. 2018 Aug;165(4):438-439.
- Velloso EP, Vieira R, Cabral AC, et al. Reduced plasma levels of angiotensin-(1-7) and renin activity in preeclamptic patients are associated with the angiotensin I-converting enzyme deletion/deletion genotype. Braz J Med Biol Res. 2007 Apr;40(4):583-90.
- Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. Pharmacol Rev. 2016 Apr;68(2):357-418.
- Unic A, Derek L, Hodak N, et al. Endothelins – clinical perspectives. Biochem Med (Zagreb). 2011;21(3):231-42.
- Levin ER. Endothelins. N Engl J Med. 1995 Aug 10;333(6):356-63.
- Tschaikowsky K, Sägner S, Lehnert N, et al. Endothelin in septic patients: effects on cardiovascular and renal function and its relationship to proinflammatory cytokines. Crit Care Med. 2000 Jun;28(6):1854-60.
- Eto M, Barandiér C, Rathgeb L, et al. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res. 2001 Sep 28;89(7):583-90.
- Adlbrecht C, Hulsmann M, Strunk G, et al. Prognostic value of plasma midregional pro-adrenomedullin and c-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail 2009;11:361-6.
- Neuhold S, Huelsmann M, Strunk G, et al. Comparison of copeptin, b-type natriuretic peptide, and amino-terminal prob-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol. 2008;52:266-72.
- Habib A, Al-Omari MA, Khaleghi M, et al. Plasma C-terminal pro-endothelin-1 is associated with target-organ damage in African Americans with hypertension. Am J Hypertens. 2010 Nov;23(11):1204-8.
- Al-Omari MA, Khaleghi M, Mosley TH Jr, et al. Plasma Cterminal pro-endothelin-1 is associated with left ventricular mass index and aortic root diameter in African-American adults with hypertension. J Hum Hypertens. 2011 Feb;25(2):106-13.
- Haryono A, Ramadhiani R, Ryanto GRT, Emoto N. Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going. Biology (Basel). 2022 May 16;11(5):759.
- Wellman S, Benzing J, Fleischlin S. Cardiovascular Biomarkers in Preeclampsia at Triage. Fetal Diagn Ther. 2014; 36:202–207.
- Malte AL, Uldbjerg N, Wright D, Torring N. Prediction of severe pre-eclampsia/HELLP syndrome by combination of sFlt1, CT-pro-ET-1, and blood pressure: exploratory study. Ultrasound Obstet Gymecol. 2018; 51: 768-774.